Lykke J, Jess P, Roikjaer O
Department of Surgery, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Department of Surgery, Roskilde Hospital, University of Copenhagen, Roskilde, Denmark.
Eur J Surg Oncol. 2016 Apr;42(4):504-12. doi: 10.1016/j.ejso.2016.01.012. Epub 2016 Jan 23.
To analyze the prognostic implications of the lymph node ratio (LNR) in curative resected rectal cancer.
It has been proposed that the LNR has a high prognostic impact in colorectal cancer, but the lymph node ratio has not been evaluated exclusively for rectal cancer in a large national cohort study.
All 6793 patients in Denmark diagnosed with stage I to III adenocarcinoma of the rectum, and so treated in the period from 2003 to 2011, were included in the analysis. The cohort was divided into two groups according to whether or not neo-adjuvant treatment had been given.
In a multivariate analysis the pN status, ypN status and lymph node yield were found to be independent prognostic factors for overall survival, irrespective of neo-adjuvant therapy. The LNR was also found to be a significant prognostic factor with a Hazard Ratio ranging from 1.154 (95% CI: 0.930-1.432) (LNR: 0.01-0.08) to 2.974 (95% CI: 2.452-3.606) (LNR > 0.5) in the group of patients who had surgery to begin with and from 1.381 (95% CI: 0.891-2.139) (LNR: 0.01-0.08) to 2.915 (95% CI: 2.244-3.787) (LNR > 0.5) in the group of patients who had neo-adjuvant treatment.
The LNR reflects the influence on survival from N-status and the lymph node yield and since LNR was shown to be a significant prognostic predictor for overall survival in patients with curatively resected stage III rectal cancer irrespective of neo-adjuvant therapy we recommend that the introduction of LNR should be considered for rectal cancer in a revised TNM classification.
分析根治性切除直肠癌中淋巴结比率(LNR)的预后意义。
有人提出LNR对结直肠癌具有较高的预后影响,但尚未在大型全国性队列研究中专门针对直肠癌评估淋巴结比率。
纳入丹麦2003年至2011年期间诊断为I至III期直肠腺癌并接受相应治疗的所有6793例患者。根据是否接受新辅助治疗将该队列分为两组。
在多变量分析中,发现pN状态、ypN状态和淋巴结收获量是总生存的独立预后因素,与新辅助治疗无关。还发现LNR是一个显著的预后因素,在初始接受手术的患者组中,风险比范围为1.154(95%CI:0.930 - 1.432)(LNR:0.01 - 0.08)至2.974(95%CI:2.452 - 3.606)(LNR > 0.5);在接受新辅助治疗的患者组中,风险比范围为1.381(95%CI:0.891 - 2.139)(LNR:0.01 - 0.08)至2.915(95%CI:2.244 - 3.787)(LNR > 0.5)。
LNR反映了N状态和淋巴结收获量对生存的影响,并且由于LNR被证明是根治性切除的III期直肠癌患者总生存的显著预后预测因素,与新辅助治疗无关,我们建议在修订的TNM分类中考虑将LNR引入直肠癌的评估。